Abstract: Disclosed herein are conjugated polymers comprising a polymer and an all-trans retinoic acid (ATRA) prodrug covalently bound to the polymer by a hydrolysable linker L or a pharmaceutically acceptable salt thereof, and methods of using same to treat certain disorders. In an embodiment, the conjugated polymer comprises poly (vinyl alcohol) covalently bound to ATRA through an ester linkage.

Abstract: Disclosed are nanoparticles comprising a polymer carrier formed from a poly(ethylene glycol) and a poly(carbonate) copolymer which encapsulates a cargo entity such as an ERK inhibitor and/or chemotherapeutic agent. Therapeutic uses of the nanoparticles are also described, including methods of treating a cancer such as pancreatic cancer.

Abstract: The invention relates to acetoacetylated lignin resin compositions comprising the reaction product of lignin and an acetoacetate ester. The invention also relates to (meth)acrylated lignin resin compositions comprising the reaction product of lignin and a (meth)acrylic compound. The invention also relates to methods of making the acetoacetylated and (meth)acrylated lignin resin compositions. The invention also relates to curable coating compositions comprising the acetoacetylated and (meth)acrylated lignin resin compositions. The invention also relates to methods of making the curable coating compositions of the invention. The invention also relates to methods of applying curable coating compositions of the invention to substrates. The invention also relates to articles of manufacture comprising a curable coating composition of the invention and a method of making such article.

Abstract: Disclosed herein are conjugated polymers comprising a polymer and an all-trans retinoic acid (ATRA) prodrug covalently bound to the polymer by a hydrolysable linker L or a pharmaceutically acceptable salt thereof, and methods of using same to treat certain disorders. In an embodiment, the conjugated polymer comprises poly (vinyl alcohol) covalently bound to ATRA through an ester linkage.

Abstract: The invention relates to a compound suited as entity carrier, having the general formula (I) wherein X is an amine-containing residue further defined herein. The invention further relates to the use of such compounds, a nanocarrier system, a kit comprising such compounds and methods for gene silencing and anti-cancer treatment.

Abstract: The invention relates to a compound suited as entity carrier, having the general formula (I) wherein X is an amine-containing residue further defined herein. The invention further relates to the use of such compounds, a nanocarrier system, a kit comprising such compounds and methods for gene silencing and anti-cancer treatment.

Abstract: Described is the use of a nanocarrier having a dendritic structure which is composed of a dendritic core and at least one shell for the non-covalent encapsulation and/or transport of divalent metal-ions, preferably Cu-ions or Zn(II) -ions. Also described is a pharmaceutical composition containing such nanocarrier complexed divalent metal-ions in a non-covalent encapsulated form. Finally several therapeutic uses of such a nanocarrier divalent metal-ion complex are described, for example for slowing down ageing or for the treatment of Cu-ion transport disorders like Alzheimer's disease (AD) or Menkes disease.